The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 13, 2019
Filed:
Nov. 19, 2015
Applicant:
Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, DE;
Inventors:
Paul Adam, Vienna, AT;
Katrin Friedbichler, Vienna, AT;
Assignee:
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, unknown;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 31/4164 (2006.01); A61K 31/4166 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 31/00 (2013.01); A61K 31/4164 (2013.01); A61K 31/4166 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01);
Abstract
The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.